

OBNM Formulary Council May 18, 2016 - Meeting Minutes

Present: Kevin Wilson, ND; John Block, PhD.; Patrick Chapman, ND; Dohn Kruschwitz, MD; Natalie Gustafson, PharmD; Anne Walsh, Executive Director. There is one vacant position still needing to be filled.

Excused:; Justin Bednar, RPh

Opened at 9:45am

September 16, 2015 Minutes: The minutes from the September 16, 2015 meeting were approved with one minor correction.

FDA New Drugs Review: The FC reviewed the FDA 2016 Drug list along with the 2015 list since it had been tabled at the September 2015 meeting

Monoclonal antibodies (mAb) although listed are considered very potent and require additional training to administer, and are not recommended for use by NDs.

Any ND with supportive documentation may apply to the FC for consideration of oncology/chemotherapy drugs. (This includes education and training)

Tacrolimus, used for organ rejection, is approved for topical use only (falls under 850-060-0226(23(k))

Palbococlib is not approved, but any ND with supportive documentation may apply to the FC for consideration

Oncology drugs were not approved

Atypical anti-psychotics will be tabled to be considered at a future meeting.

Draft rule (850-060-0223) will provide a list of drugs that are excluded from the OBNM formulary. Draft language was considered, and revisions will be made to be sent to the board.

OAR 850-060-0225: Discussion continued on the drugs listed in 850-060-0225, the original formulary list, to make sure all drugs listed would be found by classification in 850-060-0226. No additional changes were recommended and this rule is ready to be deleted in an effort to move to an exclusionary formulary.

Medical Marijuana: This is ongoing discussion. The Formulary Council still wants to see NDs be writers of medical marijuana. There was discussion on how much a ND can share/recommend to a patient. The OBNM AAG has provided an opinion which the Board will consider at the June board meeting.

Motions from FC going to the Board: FC recommends the following to the OBNM:

~ The council recommends that the OBNM write rule that it is not within the scope of practice for NDs to dispense controlled substances.

~ Add **Phenobarbital** to 850-060-0226(8)(c)(D) and move Anticonvulsants, Misc to (E)

~ Add language to 850-060-0226(26)(e) Biologic Response Modifiers, **not to used in systemic oncology**

~ Delete 850-060-0225, if adopting a rule listing the excluded drugs

~ Adopt a new rule listing the excluded prescribed drugs. Some draft language has been worked on

Council Member: There is still a vacancy; to be filled by the following qualification: “(e) two additional members appointed by the council who hold an advanced degree in a medical or pharmaceutical science”. FC discussed the goals to strive for a full council. Someone with a PhD possibly; does not need to be ND or MD, more of a “science” person or psychiatry – research area is preferable. The FC would like to look at any resume or person interested and then decide together who might be a best fit.

John Block will do some recruiting.

Next Meeting Date:

The next meeting was tentatively scheduled for September 21, 2016, 9:30am.

The meeting was adjourned at 11:55am.

From the minutes of the June 13, 2016 OBNM Meeting:

Formulary Council – P. Chapman reported on the May 18 Formulary Council meeting. He shared the FC recommendation to OBNM which would introduce a new rule defining the excluded drugs, and repeal 850-060-0225 which is no longer necessary after the FC reviewed each listed drug and determined they could all be found by classification in 850-060-0226. The FC has also recommended that the Board consider a rule to clarify that is it not within the scope of practice for NDs to dispense controlled substances. Additionally the FC approves an amendment to 850-060-0226(8)(c)(D) adding Phenobarbital; and in 850-0226(26)(e) to read Biologic Response Modifiers, **not to be used in systemic oncology.**

The OBNM did not discuss further writing a rule regarding the dispensing controlled substances.

Formulary Council Update September 21, 2016

Patrick Chapman is no longer the OBNM Representative for the Board.

The FC would like the Board to appoint a new member representative to be available for future meetings. The council meets twice a year, in March and September usually.

The FC appointed Adam Alani PhD to the position left vacant with the retirement of Ann Blair PhD in 2013.

There were no recommended additions or deletions to the formulary rules.

There was discussion again about recommending that the Board write a rule to clarify that NDs cannot order controlled substances for office use. Any drug should be properly stored and a record kept of dispensing.

Discussion was had on the use of ozone therapy. The FC believes NDs should be properly trained before utilizing any of these. They discussed recommending a rule requiring specific education and training, and then determined that the NDs using these protocols should be responsible for maintaining their own education, the board should not have to oversee this.